This table presents recent patent oppositions filed by Alnylam Pharmaceuticals, Inc. against its competitors. It outlines key details of each case, including the patent title, filing date and the applicant. This information provides insights into the competitive landscape and highlights active disputes over patent grant within the industry.

Patent NumberTitleApplicantOpposition Date
EP2978451Compositions And Methods For Increasing The Serum Half-Life Of A Therapeutic Agent Targeting Complement C5ALEXION PHARMACEUTICALS, INC.Aug 27, 2020
EP1857547Further Novel Forms Of Interfering Rna MoleculesATUGEN AGAug 17, 2018

The following table provides an overview of the latest patents of Alnylam Pharmaceuticals, Inc. that has been opposed by its competitors. It provides an insight into the competitive landscape of the industry and highlights the patents that are subject to oppositions.

Patent NumberGrant DateTitleTotal Oppositions
EP3366775Apr 27, 2022Modified Rnai Agents1
EP3656860Apr 20, 2022Angiopoietin-Like 3 (Angptl3) Irna Compositions And Methods Of Use Thereof1
EP3105331Jun 23, 2021Ketohexokinase (Khk) Irna Compositions And Methods Of Use Thereof1
EP2723758Jun 20, 2018Angiopoietin-Like 3 (Angptl3) Irna Compostions And Methods Of Use Thereof1